Pharma giant Novartis has signed Shyft, a Medidata Solutions subsidiary, to help boost its push for digital solutions to aid the launch of new therapies targeted for the European market.
As part of the agreement, Shyft will provide Novartis its Strata data platform that manages third party and proprietary commercial data sources, and the Lumen insights platform that delivers analytics for ‘next-best-actions’ for commercial teams, Medidata said.
The partnership between Novartis and Shyft come from an existing collaboration between Novartis and Medidata, which has been supporting the pharma’s clinical trials and commercialization programs.
“Medidata and Shyft have come together in a way that allows us to share data and insights seamlessly across our clinical development and commercial teams,” Bertrand Bodson, Novartis’ chief digital officer, said in a statement. “We are committed to reimagining medicine with data and digital, and this technology helps us do that by supporting our pharma sales reps with intelligence-driven ‘next-best-action’ so they can make the 100,000 interactions they have with HCPs (health-care providers) every day as personalized and meaningful as possible.”
Earlier this year, Novartis announced an executive shakeup as part of the company’s efforts to strengthen its digital presence and tighten its ethics and compliance efforts in the wake of a series of global scandals. As part of that move, Bodson—the company’s first chief digital officer—was elevated to the executive committee, reporting directly to the Novartis’ chief executive.
That move came on the heels of a deal with Pear Therapeutics to develop software applications that could got to the FDA for approval and link with prescription drugs as a way to help support value-based pricing with payers. Novartis has said one of its top goals is to use tech to improve the overall way it does business.
By Joseph Keenan
Source: Fierce Biotech
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
